Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SIR-H5255 | Human | Human SIGIRR Protein, Fc Tag (MALS verified) |  |
|
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ibudilast | AV-411; KC-404; MN-166 | Approved | Ketas, Pinatos, Eyevinal | Japan | Asthma; Multiple Sclerosis; Neuralgia | Kyorin Pharmaceutical Co Ltd | Substance-Related Disorders; HIV Infections; Opioid-Related Disorders; Headache Disorders, Secondary; Diabetic Neuropathies; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Pneumonia, Viral; Alcoholism; Asthma; Neuralgia; Amyotrophic Lateral Sclerosis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Mosedipimod | EC-18 | Phase 2 Clinical | Enzychem Lifesciences Co | Neutropenia; Coronavirus Disease 2019 (COVID-19); Stomatitis; Febrile Neutropenia; Dermatitis, Atopic | Details |
| Paridiprubart | EB-07; EB-05; NI-0101 | Phase 2 Clinical | Novimmune Sa | Coronavirus Disease 2019 (COVID-19); Pulmonary Fibrosis; Respiratory Distress Syndrome, Adult | Details |
| PEPA-10 | PEPA-10 | Phase 2 Clinical | Immunovo BV | Neoplasms | Details |
| eNamptcumab | ALT-100 | Phase 2 Clinical | Aqualung Therapeutics Corp | Ventilator-Induced Lung Injury; Respiratory Distress Syndrome, Adult; Pulmonary Fibrosis; Prostatic Neoplasms; Pulmonary Arterial Hypertension; Chorioamnionitis | Details |
| Glycopyranosyl lipid adjuvant (Immune Design) | GLA; G100; GLA-SE; ID-G100; G-100 | Phase 2 Clinical | Immune Design | HIV Infections; Skin Melanoma; Malaria, Falciparum; Tuberculosis, Pulmonary; Sarcoma; Hookworm Infections; Leishmaniasis; Schistosomiasis | Details |
| Glycopyranosyl lipid adjuvant (Revelation Biosciences) | PHAD (Revelation Biosciences); REVTx 99; REVTx-99a; REVTx-99b; REVTx-100 (Revelation Biosciences); REVTx-200 (Revelation Biosciences); REVTx-300 (Revelation Biosciences); GLA (Revelation Biosciences) | Phase 2 Clinical | Revelation Biosciences Inc | Cross Infection; Influenza A virus infections; Acute Kidney Injury; Surgical Wound Infection; Renal Insufficiency, Chronic; Myocarditis | Details |
| TARA-002(Protara Therapeutics) | TARA-002 | Phase 2 Clinical | Protara Therapeutics Inc | Urinary Bladder Neoplasms; Lymphatic Abnormalities | Details |
| ApTOLL | Phase 2 Clinical | aptaTargets SL | Stroke; Ischemic Stroke | Details | |
| Temelimab | GNN-001; GENHP-01; GNbAC-1 | Phase 2 Clinical | Geneuro Sa | Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Multiple Sclerosis; Post-Acute COVID-19 Syndrome | Details |
| GSK-1795091 | 1795091; GSK-1795091; CRX-601 | Phase 1 Clinical | Glaxosmithkline Plc | Neoplasms | Details |
| PET-lipid A | Phase 1 Clinical | Cascadian Therapeutics Inc | Vaccination | Details | |
| SAR-439794 | SAR-439794 | Phase 1 Clinical | Sanofi | Food Hypersensitivity | Details |
| INI-2004 | INI-2004 | Phase 1 Clinical | Inimmune Corp | Respiratory Tract Infections; Neoplasms; Food Hypersensitivity; Rhinitis, Allergic | Details |
This web search service is supported by Google Inc.
A-Z
